Drugs / Allogeneic Islets of Langerhans

Trials 6 · a red edge is where a trial was stopped

2000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 1/24 trials
Phase 1/2 NCT00265473 Nov 2005 → May 2010 hypoglycemia, type 1 diabetes mellitus University of Minnesota Completed No outcome recorded
Phase 1/2 NCT00286624 Mar 2003 → Aug 2006 hypoglycemia, type 1 diabetes mellitus University of Minnesota Completed No outcome recorded
Phase 1/2 NCT00285233 Sep 2000 → Sep 2004 hypoglycemia, type 1 diabetes mellitus University of Minnesota Completed No outcome recorded
Phase 1/2 NCT00285194 Apr 2000 → Jan 2004 hypoglycemia, type 1 diabetes mellitus University of Minnesota Completed No outcome recorded
Phase 21 trial
Phase 2 NCT00306098 Dec 2000 → Jul 2004 type 1 diabetes mellitus Rodolfo Alejandro Completed No outcome recorded
Phase not stated1 trial
NCT01606475 end stage renal failure, hypoglycemia, type 1 diabetes mellitus University of Minnesota No longer available No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 7 sources stand behind the page.

FieldValueCited text
Known as Allogeneic Islets of Langerhans ClinicalTrials.gov intervention name — accepted as the source's own label NCT00265473
4

NCT00285233

NCT00286624

NCT00285194

NCT01606475

Known as islets ClinicalTrials.gov intervention name — accepted as the source's own label NCT00306098
Modality Cell therapy “Islets were isolated from two-layer preserved pancreata, purified, cultured for 2 days; and transplanted into six C-peptide-negative, nonuremic, type 1 diabetic patients with...” PMID 14961992 Mar 2004
Route Other “Intraportal infusion of islets of Langerhans” NCT00265473